Immunocore to report second quarter 2026 financial results and host call on August 6, 2026

Rhea-AI Summary

Immunocore (Nasdaq: IMCR) will report its second quarter 2026 financial results for the period ended June 30, 2026, on Thursday, August 6, 2026. The company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) to discuss results and provide a business and portfolio update.

The audio webcast can be accessed via the ‘Events and Presentations’ section of Immunocore’s investor website, with a replay available for a limited time. Conference call dial-in numbers are 877-405-1239 (domestic, toll-free) and +1 201-389-0851 (international, toll).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Immunocore to report second quarter 2026 financial results and host call on August 6, 2026

(OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 30 July 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the second quarter ended June 30, 2026 on Thursday, August 6, 2026.

Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) to discuss its financial results and provide a business and portfolio update.

Audio Webcast
The call will be webcast live and can be accessed by visiting ‘Events’, under ‘Events and Presentations’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay will also be made available for a limited time.

Conference Call Details:
Domestic (toll-free): 877-405-1239
International (toll): +1 201-389-0851

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs​ in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

Contact Information

Immunocore

Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on LinkedIn: @Immunocore

Investor Relations

Ryan Baker
T: +1 617 771 5001
E: ir@immunocore.com

FAQ

When will Immunocore (NASDAQ: IMCR) report its Q2 2026 financial results?

Immunocore plans to report its second quarter 2026 financial results on Thursday, August 6, 2026. According to Immunocore, the results cover the quarter ended June 30, 2026, and will be accompanied by a live conference call and webcast for investors.

What time is Immunocore's Q2 2026 earnings call on August 6, 2026?

Immunocore’s Q2 2026 earnings call is scheduled for 8:00 a.m. EDT (1:00 p.m. BST) on August 6, 2026. According to Immunocore, the teleconference and webcast will review financial results and provide a business and portfolio update to analysts and investors.

How can investors access the Immunocore (IMCR) Q2 2026 earnings webcast?

Investors can access Immunocore’s Q2 2026 earnings webcast via the ‘Events’ section under ‘Events and Presentations’ in the Investors area of its website. According to Immunocore, a replay of the webcast will be available online for a limited time following the event.

What are the dial-in numbers for Immunocore's Q2 2026 earnings conference call?

Immunocore’s Q2 2026 earnings call dial-in numbers are 877-405-1239 for U.S. domestic toll-free and +1 201-389-0851 for international participants. According to Immunocore, these numbers provide direct access to the live teleconference on August 6, 2026.

What does Immunocore do and what is KIMMTRAK?

Immunocore is a commercial-stage biotechnology company developing TCR bispecific immunotherapies called ImmTAX. According to Immunocore, its most advanced oncology TCR therapeutic, KIMMTRAK, is approved for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma in several major markets.

Will a replay be available after Immunocore's Q2 2026 earnings webcast?

Yes, a replay of Immunocore’s Q2 2026 earnings webcast will be available online for a limited time. According to Immunocore, investors can access the replay through the ‘Events and Presentations’ section within the Investors area of the company’s website.